Retraction: Sarcosine Up-Regulates Expression of Genes Involved in Cell Cycle Progression of Metastatic Models of Prostate Cancer (PLoS ONE (2016) 11:11 (e0165830) DOI: 10.1371/journal.pone.0165830);Sarcosine up-regulates expression of genes involved in cell cycle progression of metastatic models of prostate cancer

PLoS ONE

Volumn 11, Issue 11, 2016, Pages

  Heger, Zbynek ^a,b   Rodrigo, Miguel Angel Merlos ^a,b   Michalek, Petr ^a,b   Polanska, Hana ^c   Masarik, Michal ^b,c   Vit, Vitezslav ^d   Plevova, Mariana ^d   Pacik, Dalibor ^d   Eckschlager, Tomas ^e   Stiborova, Marie ^f   Adam, Vojtech ^a,b  

^a MENDEL UNIVERSITY IN BRNO   (Czech Republic)

^b BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^e UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^f CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; COMPLEMENTARY DNA; DIMETHYLGLYCINE; GLYCINE; METHYLTRANSFERASE; SARCOSINE; SARCOSINE DEHYDROGENASE; SERINE; GLYCINE METHYLTRANSFERASE; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOINFORMATICS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE COURSE; ELECTROCHEMISTRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; IN VITRO STUDY; ION EXCHANGE CHROMATOGRAPHY; MALE; METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OVERLAPPING GENE; POLYMERASE CHAIN REACTION; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REVERSE TRANSCRIPTION; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL CYCLE; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; NUDE MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR GENE;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GLYCINE N-METHYLTRANSFERASE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; SARCOSINE; SARCOSINE DEHYDROGENASE; TRANSCRIPTOME; UP-REGULATION;

EID: 84994480527     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0268981     Document Type: Erratum

References (42)

1. Cernei N, Heger Z, Gumulec J, Zitka O, Masarik M, Babula P, et al. Sarcosine as a Potential Prostate Cancer Biomarker-A Review. Int J Mol Sci. 2013; 14(7): 13893-908. doi: 10.3390/ijms140713893 PMID: WOS: 000322171700060.
2. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu JD, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009; 457(7231): 910-4. doi: 10.1038/nature07762 PMID: WOS: 000263266700051.
3. Heger Z, Cernei N, Gumulec J, Masarik M, Eckschlager T, Hrabec R, et al. Determination of common urine substances as an assay for improving prostate carcinoma diagnostics. Oncol Rep. 2014; 31 (4): 1846-54. doi: 10.3892/or.2014.3054 PMID: WOS: 000334345600046.
4. Kumar D, Gupta A, Mandhani A, Sankhwar SN. Metabolomics-Derived Prostate Cancer Biomarkers: Factor Fiction? J Proteome Res. 2015; 14(3): 1455-64. doi: 10.1021/pr5011108 PMID: WOS: 000350840900011.
5. Heger Z, Cernei N, Krizkova S, Masarik M, Kopel P, Hodek P, et al. Paramagnetic Nanoparticles as a Platform for FRET-Based Sarcosine Picomolar Detection. Sci Rep. 2015; 5: 1-7. 8868 doi: 10.1038/srep08868 PMID: WOS: 000350549200018.
6. Ankerst DP, Liss M, Zapata D, Hoefler J, Thompson IM, Leach RJ. A case control study of sarcosine as an early prostate cancer detection biomarker. BMC Urol. 2015; 15: 1-4. 99 doi: 10.1186/s12894-015-0095-5 PMID: WOS: 000362161700001.
7. Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, Kristiansen G, et al. Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. Eur Urol. 2010; 58(1): 12-8. doi: 10.1016/j.eururo.2010.01.035 PMID: WOS: 000278414100003.
8. Heger Z, Gumulec J, Cernei N, Polanska H, Raudenska M, Masarik M, et al. Relation of exposure to amino acids involved in sarcosine metabolic pathway on behavior of non-tumor and malignant prostatic cell lines. Prostate. 2016; 76(7): 679-90. doi: 10.1002/pros.23159 PMID: WOS: 000373932700007.
9. Sudhakaran PR, Binu S, Soumya SJ. Effect of sarcosine on endothelial function relevant to angiogene-sis. J Canc Res Ther. 2014; 10(3): 603-10. doi: 10.4103/0973-1482.137945 PMID: WOS: 000346890600028.
10. Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, et al. The Role of Sarcosine Metabolism in Prostate Cancer Progression. Neoplasia. 2013; 15(5): 491-501. doi: 10.1593/neo.13314 PMID: WOS: 000324486500004.
11. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001; 411(6835): 342-8. doi: 10.1038/35077213 PMID: WOS: 000168710000056.
12. Geschwind DH DNA microarrays: translation of the genome from laboratory to clinic. Lancet Neurol. 2003; 2(5): 275-82. doi: 10.1016/s1474-4422(03)00379-x PMID: WOS: 000182363400015.
13. Lipshutz RJ, Fodor SPA, Gingeras TR, Lockhart DJ. High density synthetic oligonucleotide arrays. Nature Genet. 1999; 21: 20-4. doi: 10.1038/4447 PMID: WOS: 000078008200007.
14. Heger Z, Cernei N, Kudr J, Gumulec J, Blazkova I, Zitka O, et al. A Novel Insight into the Cardiotoxicity of Antineoplastic Drug Doxorubicin. Int J Mol Sci. 2013; 14(11): 21629-46. doi: 10.3390/ijms141121629 PMID: WOS: 000328624400027.
15. Roth KM, Peyvan K, Schwarzkopf KR, Ghindilis A. Electrochemical detection of short DNA oligomer hybridization using the CombiMatrix ElectraSense Microarray reader. Electroanalysis. 2006; 18(19-20): 1982-8. doi: 10.1002/elan.200603603 PMID: WOS: 000241621300017.
16. Heger Z, Michalek P, Guran R, Havelkova B, Kominkova M, Cernei N, et al. Exposure to 17beta-Oestradiol Induces Oxidative Stress in the Non-Oestrogen Receptor Invertebrate Species Eiseniafetida. PLoS One. 2015; 10(12). e0145426 doi: 10.1371/journal.pone.0145426 PMID: WOS: 000367092500046.
17. Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 2010; 38: D355-D60. doi: 10.1093/nar/gkp896 PMID: WOS: 000276399100055.
18. Ding ZH, Wu CJ, Chu GC, Xiao YH, Ho D, Zhang JF, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011; 470(7333): 269-73. doi: 10.1038/nature09677 PMID: WOS: 000287144200046.
19. Tomlins SA, Aubin SMJ, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, et al. Urine TMPRSS2: ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA. Sci Transl Med. 2011; 3(94). 94ra72 doi: 10.1126/scitranslmed.3001970 PMID: WOS: 000293459700006.
20. Heiden MGV, Cantley LC, Thompson CB. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science. 2009; 324(5930): 1029-33. doi: 10.1126/science.1160809 PMID: WOS: 000266246700031.
21. Locasale JW Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer. 2013; 13(8): 572-83. doi: 10.1038/nrc3557 PMID: WOS: 000322158200011.
22. Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends BiochemSci. 2014; 39(4): 191-8. doi: 10.1016/j.tibs.2014.02.004 PMID: WOS: 000335426200007.
23. Brosnan ME, MacMillan L, Stevens JR, Brosnan JT. Division of labour: how does folate metabolism partition between one-carbon metabolism and amino acid oxidation? Biochem J. 2015; 472: 135-46. doi: 10.1042/bj20150837 PMID: WOS: 000369171700002.
24. Marchetti C, Palaia I, Giorgini M, De Medici C, Iadarola R, Vertechy L, et al. Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. OncoTargets Ther. 2014; 7: 1223-36. doi: 10.2147/ott.s40947 PMID: WOS: 000338714100001.
25. Yoon JK, Kim DH, Koo JS. Implications of differences in expression of sarcosine metabolism-related proteins according to the molecular subtype of breast cancer. J Transl Med. 2014; 12. 149 doi: 10.1186/1479-5876-12-149 PMID: WOS: 000338471000001.
26. Green T, Chen XF, Ryan S, Asch AS, Ruiz-Echevarria MJ. TMEFF2 and SARDH cooperate to modulate one-carbon metabolism and invasion of prostate cancer cells. Prostate. 2013; 73(14): 1561-75. doi: 10.1002/pros.22706 PMID: WOS: 000323450800008.
27. Burdelski C, Strauss C, Tsourlakis MC, Kluth M, Hube-Magg C, Melling N, et al. Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer. Oncotarget. 2015; 6(10): 8377-87. PMID: WOS: 000354885300075. doi: 10.18632/oncotarget.3107
28. Brody JR, Hucl T, Costantino CL, Eshleman JR, Gallmeier E, Zhu H, et al. Limits to Thymidylate Synthase and TP53 Genes as Predictive Determinants for Fluoropyrimidine Sensitivity and Further Evidence for RNA-Based Toxicity as a Major Influence. Cancer Res. 2009; 69(3): 984-91. doi: 10.1158/0008-5472.can-08-3610 PMID: WOS: 000263048700034.
29. Park K, Chen ZM, MacDonald TY, Siddiqui J, Ye HH, Erbersdobler A, et al. Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. Hum Pathol. 2014; 45(10): 2136-43. doi: 10.1016/j.humpath.2014.06.008 PMID: WOS: 000343528200020.
30. Zhou XJ, Zhang ZY, Yang X, Chen WT, Zhang P. Inhibition of cyclin D1 expression by cyclin D1 shRNAs in human oral squamous cell carcinoma cells is associated with increased cisplatin chemo-sensitivity. Int J Cancer. 2009; 124(2): 483-9. doi: 10.1002/ijc.23964 PMID: WOS: 000262010600032.
31. Mukai S, Yorita K, Yamasaki K, Nagai T, Kamibeppu T, Sugie S, et al. Expression of human kallikrein 1-related peptidase 4 (KLK4) and MET phosphorylation in prostate cancer tissue: immunohistochemical analysis. Hum Cell. 2015; 28(3): 133-42. doi: 10.1007/s13577-015-0114-6 PMID: WOS: 000358902800004.
32. Kote-Jarai Z, Al Olama AA, Leongamornlert D, Tymrakiewicz M, Saunders E, Guy M, et al. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet. 2011; 129(6): 687-94. doi: 10.1007/s00439-011-0981-1 PMID: WOS: 000290540900010.
33. Wang HF, Gao X, Lu X, Wang Y, Ma CF, Shi ZK, et al. The mitotic regulator Hec1 is a critical modulator of prostate cancer through the long non-coding RNA BX647187 in vitro. Biosci Rep. 2015; 35. e00273 doi: 10.1042/bsr20150003 PMID: WOS: 000368296800009.
34. Chen YM, Riley DJ, Zheng L, Chen PL, Lee WH. Phosphorylation of the mitotic regulator protein Hec1 by Nek2 kinase is essential for faithful chromosome segregation. J Biol Chem. 2002; 277(51): 49408-16. doi: 10.1074/jbc.M207069200 PMID: WOS: 000180028900040.
35. Cooper CR, Graves B, Pruitt F, Chaib H, Lynch JE, Cox AK, et al. Novel surface expression of reticulo-calbin 1 on bone endothelial cells and human prostate cancer cells is regulated by TNF-alpha. J Cell Biochem. 2008; 104(6): 2298-309. doi: 10.1002/jcb.21785 PMID: WOS: 000258387200031.
36. Deutsch AJA, Angerer H, Fuchs TE, Neumeister P. The Nuclear Orphan Receptors NR4A as Therapeutic Target in Cancer Therapy. Anti-Cancer Agents Med Chem. 2012; 12(9): 1001-14. PMID: WOS: 000310055000001.
37. Kim MJ, Jung WH, Koo JS. Expression of sarcosine metabolism-related proteins in estrogen receptor negative breast cancer according to the androgen receptor and HER-2 status. Int J Clin Exp Pathol. 2015; 8(7): 7967-77. PMID: WOS: 000361538900032.
38. Dahl M, Bouchelouche P, Kramer-Marek G, Capala J, Nordling J, Bouchelouche K. Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells. Mol Biol Rep. 2011; 38(7): 4237-43. doi: 10.1007/s11033-010-0442-2 PMID: WOS: 000294362500001.
39. Tiwari N, Meyer-Schaller N, Arnold P, Antoniadis H, Pachkov M, van Nimwegen E, et al. Klf4 Is a Transcriptional Regulator of Genes Critical for EMT, Including Jnk1 (Mapk8). PLoS One. 2013; 8(2). e57329 doi: 10.1371/journal.pone.0057329 PMID: WOS: 000316849500090.
40. Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK signalling pathways in the regulation of cell survival. Faseb J. 2008; 22(4): 954-65. doi: 10.1096/fj.06-7859rev PMID: WOS: 000254581000003.
41. Chien CS, Shen KH, Huang JS, Ko SC, Shih YW. Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells. Mol Cell Biochem. 2010; 333(1-2): 169-80. doi: 10.1007/s11010-009-0217-z PMID: WOS: 000272869200020.
42. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008; 8(4): 253-67. doi: 10.1038/nrc2347 PMID: WOS: 000254133500014.